In this episode of The Brainstorm, Sam, Nick, and Brett break down Merck and Moderna’s positive Phase 3 results for a personalized mRNA cancer vaccine, a treatment custom-built from each patient’s own tumor that cut mortality from advanced melanoma by roughly 50% versus the standard of care. The team digs into cost, manufacturing scale, and why the capital poured into mRNA during COVID may be paying off in oncology. Then Brett reports back from a weekend with Grok Bot, which recovered $75 of his wife’s forgotten escrow money on its first task, and the team debates why multiplayer agents could be the real threat to Microsoft’s enterprise moat.
Key Points From This Episode:
How a custom mRNA vaccine trains the immune system against a patient’s own tumor, and what Phase 3 melanoma results could mean for other cancers
Why $200K–$300K per treatment limits early use, and what we believe has to change for personalized oncology to scale
Why agents that live inside team chat, not one-on-one, may be the real disruption to Microsoft and Slack
If you know ARK, you know we focus on long-term innovation. But that doesn’t mean we ignore breaking news. Every day, we debate the latest developments in tech and markets. Now, we’re bringing those conversations to you in “The Brainstorm,” a co-production from ARK, WOLF, and Public. Tune in weekly for our quick takes on what’s shaping innovation right now.
Podden och tillhörande omslagsbild på den här sidan tillhör
ARK Invest. Innehållet i podden är skapat av ARK Invest och inte av,
eller tillsammans med, Poddtoppen.
